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Abstract
Parkinson disease (PD) is the second most common neu-
rodegenerative disorder after Alzheimer disease, whereas
Gaucher disease (GD) is the most frequent lysosomal storage
disorder caused by homozygous mutations in the glucocere-
brosidase (GBA1) gene. Increased risk of developing PD has
been observed in both GD patients and carriers. It has been
estimated that GBA1 mutations confer a 20- to 30-fold
increased risk for the development of PD, and that at least
7–10% of PD patients have a GBA1 mutation. To date,
mutations in the GBA1 gene constitute numerically the most
important risk factor for PD. The type of PD associated with
GBA1 mutations (PD-GBA1) is almost identical to idiopathic
PD, except for a slightly younger age of onset and a tendency
to more cognitive impairment. Importantly, the pathology of
PD-GBA1 is identical to idiopathic PD, with nigral dopamine
cell loss, Lewy bodies, and neurites containing alpha-
synuclein. The mechanism by which GBA1mutations increase
the risk for PD is still unknown. However, given that clinical
manifestation and pathological ﬁndings in PD-GBA1 patients
are almost identical to those in idiopathic PD individuals, it is
likely that, as in idiopathic PD, alpha-synuclein accumulation,
mitochondrial dysfunction, autophagic impairment, oxidative
and endoplasmic reticulum stress may contribute to the
development and progression of PD-GBA1. Here, we review
the GBA1 gene, its role in GD, and its link with PD.
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Glucocerebrosidase 1 gene
The human glucocerebrosidase 1 (GBA1) gene maps to the
1q21 region and consists of 11 exons within a 7.6 kb
sequence (Horowitz et al. 1989; Cormand et al. 1997).
Approximately, 16 kb downstream of GBA1 lies an almost
identical sequence consisting of 11 exons within a 5.7 kb
sequence (Horowitz et al. 1989; Sorge et al. 1990). Despite
large deletions of Arthrobacter luteus sequences ﬂanked by
direct repeats in the introns, this pseudogene shares 96%
coding sequence similarity with the functional gene (Horow-
itz et al. 1989). As some mutations found in the functional
gene can naturally occur within the pseudogene, the presence
of the highly homologous pseudogene in close proximity to
the functional gene complicates molecular identiﬁcation of
known and novel GBA1 mutations. Therefore, a method
allowing the GBA1 gene to be distinguished from the
pseudogene is crucial for reliable molecular diagnosis. One
such method utilizes a long-template polymerase chain
reaction (PCR) where genomic fragments of differing lengths
from both the gene and the pseudogene are ampliﬁed
simultaneously, before being puriﬁed and subsequently used
for mutation identiﬁcation (Tayebi et al. 1996).
Northern blot analysis revealed the existence of at least
two GBA1 mRNAs (2.2 and 2.6 kb in length) that arise as a
result of alternate polyadenylation sites (Horowitz et al.
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1989).The GBA1 mRNA has two in-frame methionine start
codons located in exons 1 and 2, and both methionines are
translated to produce functional protein in vitro (Sorge et al.
1985, 1987a). The protein using the start codon in exon 1
contains a 39-amino acid signal peptide, while the protein
arising from the start codon in exon 2 contains only a 19-
amino acid signal peptide. Both are processed to a 496-amino
acid long mature protein after their signal peptide sequences
are removed, which is a common occurrence for secreted
proteins like glucocerebrosidase (Sorge et al. 1987b).
GBA1 encodes glucocerebrosidase (GCase), a lysosomal
enzyme that catalyses the hydrolysis of glycolipid gluco-
cerebroside to ceramide and glucose (Beutler 1992). Gluco-
cerebrosidase is ubiquitously expressed in all types of tissues
(The Human Protein Atlas). As with other lysosomal
proteins, GCase is synthetized in the rough endoplasmic
reticulum (ER). However, in contrast to the majority of other
lysosomal proteins, transport of GCase from the ER to
lysosomes is not mediated by mannose-6-phosphate recep-
tors, but via lysosomal membrane protein 2 (LIMP2). GCase
binds to a coiled-coil domain in the lumenal region of LIMP2
at neutral pH of the ER, and both proteins persist together
through the Golgi apparatus and endosomes into the
lysosome, where acidic pH facilitates their dissociation
(Reczek et al. 2007). Sequential traversing of GCase and the
LIMP2 complex is dependent on two phosphatidylinositol 4-
kinases (PI4Ks), with the catalytic activity of the PI4K type
IIIb (PI4KIIIb) kinase required for exit of the complex from
the Golgi apparatus, and the PI4K type IIa (PI4KIIa) kinase
needed for correct sorting of the complex from endosomes to
lysosomes (Jovic et al. 2012).
The crystal structure of GCase, ﬁrst obtained in 2003,
revealed that GCase has three non-continuous domains.
Domain I consists of a three-stranded anti-parallel b-sheet. It
contains two disulphide bridges, which may be involved in
GCase folding. Domain II consists of two b-sheets that form
an immunoglobulin-like domain. Finally, domain III consists
of an eight-stranded b/a triose phosphate isomerase (TIM)
barrel and contains the catalytic site of GCase (Dvir et al.
2003).
The human GCase is glycosylated at four out of ﬁve
available asparagine residues (N19, N59, N146, and N270,
but not N462), and glycosylation is required for its catalytic
function. It has been shown that mutations of asparagine
residues N59, N146, and N270 do not affect GCase catalytic
function and GCase interaction with active site-directed
inhibitors and activators. However, mutations of asparagine
residue N19 result in production of catalytically inactive
enzyme (Berg-Fussman et al. 1993).
Gaucher disease
Gaucher disease (GD) is named after Dr Philippe Gaucher
who, in 1882, ﬁrst described a young woman with an
enlarged spleen containing unusual looking cells (Gaucher
1882). GD is the most common autosomal recessive
lysosomal storage disorder. Its most characteristic hallmark
is the presence of glucocerebroside-laden macrophages in the
liver, spleen, and bone marrow, known as Gaucher cells. The
most common clinical features of GD include hep-
atosplenomegaly, thrombocytopenia, anemia, bone involve-
ment with osteopenia, osteoporosis, and bone pain because
of bone infarcts or pathological fractures (Beutler and
Grabowski 2001). GD has been traditionally divided into
three distinct clinical forms based on age of onset and
involvement of the central nervous system (CNS) (Cox and
Schoﬁeld 1997). Type 1 GD (OMIM, #230800) is by far the
most common form and is classiﬁed as non-neuronopathic
since it does not affect the CNS. The disease course of type 1
GD is very heterogeneous with some patients developing ﬁrst
symptoms in early childhood and others not manifesting any
symptoms until well into adulthood. Type 2 and type 3 GD
are classiﬁed as neuronopathic forms. Type 2 GD (OMIM,
#230900) is the acute neuronopathic form with onset in
infancy. It is characterized by rapid progression of neuro-
logical symptoms leading to death within 2 years of age.
Infants are apparently normal for the ﬁrst few months of life,
after which they display hepatosplenomegaly, developmental
regression, growth arrest, and rapid neurological decline
(Stone et al. 2000). Type 3 GD (OMIM, #231000) is a
chronic neuronopathic form with onset in early childhood.
Unlike type 2, it is characterized by slow progression of
neurological symptoms with parallel manifestation of all
clinical symptoms diagnosed in type 1 GD leading to death
in early adulthood (Beutler and Grabowski 2001). The
prevalence of GD in the general population is about
1/40 000–1/50 000 live births, while the incidence of GD
among Jews of Ashkenazi origin is up to 1/450 live births
with a carrier frequency of about 6% (Grabowski 2008;
National Organization of Rare Disorders 2013; Bronstein
et al. 2014).
GD is caused by mutations in the GBA1 gene that lead to
deﬁciency of the lysosomal enzyme glucocerebrosidase
(GCase). Nearly, 300 pathogenic changes in GBA1, includ-
ing point mutations, splice-site mutations, deletions, inser-
tions, and recombinant alleles containing genomic sequences
of both the gene and pseudogene, have been identiﬁed
(Hruska et al. 2008). These alterations lead to production of
misfolded mutant enzymes with signiﬁcantly reduced activ-
ity. GCase activity in GD patients is typically only 10–20%
of that in normal individuals, while GCase activity in carriers
is about 50%. It is thought that, not only GCase deﬁciency,
but also ER stress triggered by the presence of misfolded
GCase contribute to the pathogenesis of GD. The two most
common GBA1 mutations identiﬁed in GD patients are
N370S and L444P (Sidransky and Lopez 2012). Interest-
ingly, the type of mutation is broadly predictive of GD form,
as patients homozygous or compound heterozygous for the
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N370S mutation exclusively develop type 1 GD, patients
homozygous for the L444P mutation are most likely to
develop type 3 GD, while patients identiﬁed with a complex
allele and a heterozygous L444P mutation are most likely to
develop type 2 GD (Grabowski 2008; Sidransky 2012). The
severity of the GD phenotype in relation to the observed
mutation might be explained by the effect, which the
particular mutation has on the GCase structure. Namely,
the N370S mutation, which is situated on the longest a-helix
of GCase at the interface of domain II and III, does not
directly affect the catalytic activity of GCase since it located
too far from the catalytic site of domain III. The L444P
mutation, which is situated at the hydrophobic core of
domain II, causes conformational changes to the core and to
domain II, which might result in the generation of unstable
GCase (Dvir et al. 2003).
Currently, two types of treatment are available for patients
with GD: enzyme replacement therapy (using imiglucerase,
velaglucerase alfa, or taliglucerase alfa) and substrate
reduction therapy (using misglustat) (Bennett and Mohan
2013). Although these treatments greatly improve the
peripheral (non-neuronopathic) features of the disease, they
are ineffective for treatment of neuronopathic symptoms of
type 2 and type 3 GD as they do not cross the blood–brain
barrier (Bennett and Mohan 2013). Emerging treatments in
the form of small molecular chaperones designed to cross the
blood–brain barrier, which are able to bind misfolded mutant
GCase in the endoplasmic reticulum, help its correct folding
and subsequently assist its transport to the lysosomes, give
great promise for treatment of the neuronopathic features of
GD. The ability of small molecular chaperones to bind to
misfolded GCase (and subsequently to induce proper folding
of mutant GCase that in turn would increase functional
GCase levels in the lysosomes) is particularly important, as it
has been shown that majority of GBA1 mutations lead to the
production of misfolded GCase (Sawkar et al. 2002; Bernier
et al. 2004; Suzuki et al. 2009; Patnaik et al. 2012). Several
such small molecular chaperones that lead to an increase in
GCase activity have been investigated in both cell and animal
models (Sawkar et al. 2002; Bernier et al. 2004; Steet et al.
2006; Maegawa et al. 2009; Bendikov-Bar et al. 2011;
Patnaik et al. 2012; Bendikov-Bar et al. 2013; Luan et al.
2013). GCase inhibitors (e.g. N-(n-nonyl)deoxynojirimycin,
and isofagomine) were the ﬁrst chaperones shown to increase
GCase activity. Both N-(n-nonyl)deoxynojirimycin and
isofagomine increased GCase activity by increasing GCase
trafﬁcking to the lysosomes through speciﬁc, but reversible
binding of GCase in the ER. Although they led to an increase
in GCase activity in ﬁbroblasts derived from Gaucher
patients, it has been demonstrated that their clinical appli-
cation is compromised because of difﬁculties in balancing
chaperone activity with the direct inhibition of GCase
activity (Sawkar et al. 2002; Bernier et al. 2004; Steet et al.
2005). Subsequently, a class of pyrazolopyrimidines, the ﬁrst
non-inhibitory small molecular chaperones, was discovered.
The pyrazolopyrimidines act as GCase activators that lead to
both an increase in GCase translocation to the lysosomes and
in GCase activity in wild-type and mutant (N370S/N370S
and L444P/L444P) human ﬁbroblasts (Patnaik et al. 2012).
Another promising small molecular chaperone, ambroxol
hydrochloride (from now on commonly referred to as
ambroxol), was identiﬁed after screening the library of Food
and Drug Administration-approved drugs with a thermal
denaturation assay using wild-type GCase (Maegawa et al.
2009). Ambroxol has long been used to treat airway mucus
hypersecretion and hyaline membrane disease in newborns,
which demonstrates its non-toxicity to humans. Ambroxol
acts as a GCase mixed-type inhibitor with its inhibitory
property toward GCase being highest at the neutral pH of the
endoplasmic reticulum and void at the acidic pH of the
lysosomes where functional GCase is required (Maegawa
et al. 2009). Several studies have demonstrated that
ambroxol treatment of different lines of cultured human
GD ﬁbroblasts results in a signiﬁcant increase in GCase
activity (Maegawa et al. 2009; Bendikov-Bar et al. 2011,
2013; Luan et al. 2013; McNeill et al. 2014). However,
whether an increase in GCase activity is because of
ambroxol’s chaperone activity alone remains to be clariﬁed,
as it has been shown in a ﬁbroblast model that ambroxol
increased GCase activity by activating the coordinated
lysosomal expression and regulation network (coordinated
lysosomal expression and regulation) via the action of
transcription factor EB, which in turn led to an increase in
lysosomal biogenesis. An enhancement of lysosomal mass
would most likely lead to an increase in GCase activity, not
necessarily via the elevated chaperone activity of ambroxol
(McNeill et al. 2014). Currently available data from
ambroxol-treated wild-type and transgenic mice carrying
human GBA1 mutations has convincingly shown increase in
GCase activity in the peripheral organs, but variable change
in the brain. Hence, more studies are required to determine
the effect of ambroxol on GCase activity in the CNS (Luan
et al. 2013; Sanders et al. 2013).
The link between GBA1 and Parkinson disease
The link between GD and Parkinson disease (PD) was
initially regarded as incidental, thus the ﬁrst publications
describing Gaucher patients with Parkinsonian features
originated from individual clinics (McKeran et al. 1985;
Turpin et al. 1988; Tayebi et al. 2001). The increasing
number of reports suggesting the association between
mutations in the GBA1 gene and PD led to more compre-
hensive studies focusing on several Gaucher patients with PD
(Bembi et al. 2003; Tayebi et al. 2003; Varkonyi et al.
2003). Moreover, an increased proportion of PD cases in GD
carriers compared to the general population further indicated
the association of the GBA1 gene with PD (Goker-Alpan
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et al. 2004; Halperin et al. 2006). This ﬁnding led
researchers to investigate whether the frequency of GBA1
mutations is increased in PD. The ﬁrst such study identiﬁed
GBA1 mutations in 12 of 57 (21%) PD postmortem brains
(Lwin et al. 2004). This study not only further supported the
link between GBA1 and PD, but also indicated that both
heterozygous and homozygous mutations in GBA1 might be
associated with PD. Subsequently, multiple PD patients were
investigated to establish the prevalence of GBA1 mutations,
which highlighted the importance of routine GBA1 mutation
screening when diagnosing PD individuals. The approach
taken by different research groups varied, as some screened
only for the most common GBA1 mutations, while others
sequenced all exons of the gene (Tables 1–3). Overall, data
acquired from multiple studies showed that the frequency of
heterozygous GBA1 mutations varied between 2.3–9.8% in
the European population of non-Ashkenazi Jewish origin,
16.9–31.3% in the European population of Ashkenazi Jewish
origin, 1.8–8.7% in the Asian population, and 2.9–8.0% in
the combined North–South American population (Tables
1–3). The most common mutations identiﬁed in the European
population of non-Ashkenazi Jewish origin were L444P and
N370S, and both mutations were found with similar
frequency (Table 1). Interestingly, in the European popula-
tion of Ashkenazi Jewish origin, the N370S mutation was the
most predominant, while in the Asian and North–South
American populations, the L444P mutation was the most
prevalent (Tables 1–3). Moreover, most studies conducted
on European PD individuals of Ashkenazi Jewish origin did
not detect any L444P mutations, while the majority of studies
carried out on PD patients from the Asian population did not
identify any N370S mutations (Tables 1 and 2). Neverthe-
less, given the observed discrepancies in incidence of GBA1
mutations within the same population, and the limited
number of cases and controls available for individual studies,
a much bigger study was required to provide a conclusive
answer about the frequency of GBA1 mutations among
people of different origin. A multicenter meta-analysis
collected a total of 5691 PD patients and 4898 controls
(Sidransky et al. 2009). They analyzed 780 PD individuals
and 387 controls of Ashkenazi Jewish origin for both the
N370S and L444P mutations, and found that 15% of patients
and 3% of controls had one of the two mutations. They also
screened 4911 PD individuals and 4511 controls of non-
Ashkenazi Jewish origin and found that 3% of patients and
less than 1% of controls had at least one of the two
mutations. Finally, they sequenced the entire GBA1 gene in
1883 PD individuals of non-Ashkenazi Jewish origin and
found that 7% of patients carried GBA1 mutations. To
summarize, mutations in the GBA1 gene constitute numer-
ically the most important predisposing risk factor for
developing PD. Both homozygous and heterozygous GBA1
confer a 20- to 30-fold increased risk for the development of
PD, and it is estimated that approximately 5–10% of PD
patients have a GBA1 mutation (Sidransky et al. 2009;
Bultron et al. 2010; McNeill et al. 2012a,b). However, not
all GBA1 mutant carriers will develop PD, and it is currently
estimated that 30% will develop the disease by age 80 years
(Lesage and Brice 2009; Lesage et al. 2011).
GBA1-associated PD (PD-GBA1) – clinical and
biochemical presentation
Individual PD patients with GBA1 mutations cannot be
distinguished at the clinical level from idiopathic PD patients
without GBA1 mutations. Parkinson-GBA1 (PD-GBA1)
patients exhibit the classic triad of bradykinesia, rigidity,
and tremor, with asymmetric onset (Goker-Alpan et al.
2008). However, age of onset tends to be slightly younger, an
incidence of neuropsychiatric features (such as depression,
anxiety, hallucination, and sleep disturbance) is higher, and
there is a greater risk for earlier and more prevalent cognitive
impairment in PD-GBA1 patients (Tan et al. 2007; Neumann
et al. 2009; Sidransky et al. 2009; Brockmann et al. 2011;
McNeill et al. 2012b; Winder-Rhodes et al. 2013). The
pattern of cognitive dysfunction in GBA1-positive carriers is
subtly different, present in those even without PD at the time
of investigation (Zokaei et al. 2014). Nigrostriatal imaging
with ﬂuorodopa positron emission tomography or single
photon emission tomography with dopamine sensitive
ligands in PD-GBA1 demonstrate an asymmetric pattern of
abnormality indistinguishable from idiopathic PD (Goker-
Alpan et al. 2012; McNeill et al. 2013b). This contrasts with
the imaging of parkin (parkin RBR E3 ubiquitin protein
ligase, PARK2) or phosphatase and tensin homolog-induced
putative kinase 1 (PINK1) mutant PD, where abnormalities
are usually symmetrical. Patients with GBA1 mutations also
exhibit retinal thinning as determined by optical coherence
tomography compared to matched controls and similar to that
seen in PD patients (McNeill et al. 2013a).
Current evidence suggests that GBA1 mutant homozygote
and heterozygote carriers without clinical evidence of PD,
exhibit the prodromal features of the disease. Olfactory
function and cognitive assessment were signiﬁcantly
reduced, and motor testing abnormal in GBA1-positive cases
without features of PD compared to controls (McNeill et al.
2012b). A 2 year follow-up showed signiﬁcant deterioration
in scores for depression, rapid eye movement sleep behavior
disorder, cognition, olfaction, and motor scores (Beavan
et al. 2015). The GBA1 cohort exhibits a relatively rapid
evolution of non-motor and motor features.
The response to dopaminergic therapy in PD-GBA1
appears to be the same as that seen in idiopathic PD (Ziegler
et al. 2007)., including the development of motor complica-
tions. In one center, retrospective genetic analysis identiﬁed
GBA1 mutations in 17% of those who had undergone deep-
brain stimulation, and in whom clinical effect was as good as
those without mutations (Angeli et al. 2013).
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Importantly, the pathology of PD-GBA1 is identical to that
of idiopathic PD with nigral dopamine loss and Lewy bodies
and neurites containing alpha-synuclein (Westbroek et al.
2011; Swan and Saunders-Pullman 2013).
Pathogenesis of PD-GBA1
The mechanism by which GBA1 mutations increase the risk
of PD is still unknown. However, given that clinical
manifestation and pathological ﬁndings are almost identical
in PD-GBA1 and idiopathic PD patients, it is thought that, as
in idiopathic PD, alpha-synuclein accumulation, mitochon-
drial impairment, autophagic dysfunction, inﬂammation, and
oxidative and endoplasmic reticulum stress may play an
important role in both the development and progression of
PD-GBA1 (Schapira and Tolosa 2010).
In contrast to autosomal recessive forms of PD (caused by
homozygous mutations in PARK2, PINK1, or DJ-1) and
autosomal dominant forms of PD (caused by heterozygous
mutations in alpha-synuclein (SNCA) or leucine-rich repeat
kinase 2), PD-GBA1 supports both autosomal recessive and
autosomal dominant modes of inheritance (Sidransky 2012).
Autosomal recessive inheritance is generally associated
with loss-of-function of mutated proteins, and several
characteristics of GBA1 suggest loss-of-function of mutated
GCase.
• A subset of PD-GBA1 patients is identiﬁed with null
GBA1 alleles, such as 84GG and IVS2+1G>A, which do
not encode GCase (Aharon-Peretz et al. 2004; Gan-Or
et al. 2008; Clark et al. 2009).
• Inhibition of GBA1 with condruitol b-epoxide (CBE) in
cell and animal models leads to alpha-synuclein accumu-
lation (Manning-Bog et al. 2009; Cleeter et al. 2013).
• Homozygous knock-out of the Gba1 gene in mice leads
to mitochondrial dysfunction, and lipid and alpha-
synuclein accumulation (Enquist et al. 2007; Osellame
et al. 2013).
Autosomal dominant inheritance is often associated with
gain-of-function of mutated proteins, and several features of
GBA1 suggest gain-of-function of mutated GCase.
• Most PD-GBA1 patients are identiﬁed with heterozygous
GBA1 mutations.
• The missense mutations resulting in production of
misfolded GCase account for the majority of GBA1
mutations.
• Misfolded GCase interacts directly with alpha-synuclein,
which subsequently leads to increased alpha-synuclein
accumulation (Sidransky and Lopez 2012).
Even though there is evidence supporting loss- and gain-
of-function of GCase, both hypotheses have limitations, as
presence of null mutations in some PD-GBA1 patients
contradicts the gain-of-function theory, while development
of PD-GBA1 in individuals carrying heterozygous GBA1Ta
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mutations contradicts the loss-of-function theory. Further-
more, misfolded GCase and loss-of-function may result in a
secondary gain-of-function-type effect through ER trapping
and ER-associated degradation process (ERAD). Even more
importantly, neither the loss- nor gain-of-function hypotheses
explain why the majority of individuals with GBA1 muta-
tions do not develop PD.
GCase and alpha-synuclein
PD-GBA1 belongs to a group of diseases collectively known
as synucleinopathies, which are characterized by the pres-
ence of Lewy bodies and neurites containing SNCA. The
importance of SNCA in the pathology of PD-GBA1
prompted a question about the GCase and SNCA relation-
ship. To date, three main hypotheses linking GCase with
alpha-synuclein have been suggested.
The ﬁrst proposes that a gain-of-function by the misfolded
GCase results in its direct interaction with alpha-synuclein,
which then leads to increased SNCA accumulation and
aggregation (Sidransky and Lopez 2012). This would require
that GCase is able to interact directly with SNCA, and that
GCase is present in abnormal protein aggregates containing
SNCA, such as Lewy bodies. Indeed, direct interaction
between GCase and the C-terminus of SNCA was shown to
occur in lysosomes (Yap et al. 2011). The presence of GCase
in the brain tissues samples from PD-GBA1 patients was
detected in 32–90% of Lewy bodies and neurites, showing
that mutant GCase and SNCA co-localize in vivo (Goker-
Alpan et al. 2010). One piece of evidence supporting a gain-
of-function by the misfolded GCase was provided by a cell
model study, where over-expression of mutant GCase
(containing N370S, L444P, D409H, D409V, E235A, or
E340A) in neural MES23.6 and pheochromocytoma (PC12)
cells led to a 21 to 148% increase in SNCA levels (Cullen
et al. 2011). The relationship between misfolded GCase and
SNCA was further strengthened by animal model studies.
Namely, a progressive increase in SNCA levels was shown
in the hippocampus of a homozygous D409V Gba1 mouse
model, and a signiﬁcant increase in SNCA levels was
detected in the forebrain and cerebellum of hypomorphic
prosaposin mice carrying the homozygous V394L Gba1
mutation (Cullen et al. 2011; Sardi et al. 2013). Also, a
progressive increase in SNCA levels, from low levels to
substantial SNCA aggregates, was observed in the cortex of
hypomorphic prosaposin mice carrying the homozygous
D409H Gba1 mutation (Xu et al. 2014).
The second hypothesis proposes that a loss-of-function of
GCase (GCase deﬁciency because of, for example, degrada-
tion of the misfolded enzyme) leads to accumulation of a
substrate (glucocerebroside) that in turn perturbs lipid
homeostasis and subsequently affects alpha-synuclein traf-
ﬁcking, processing, and clearance. This eventually promotes
alpha-synuclein aggregation and facilitates alpha-synuclein
oligomer formation (Mazzulli et al. 2011; Westbroek et al.
2011; Sidransky and Lopez 2012). Further evidence sup-
porting this hypothesis and its consequences on SNCA
accumulation was provided from cell and animal model
studies examining the effect of GBA1 inhibition by CBE
(Manning-Bog et al. 2009; Cleeter et al. 2013). Namely,
treatment of differentiated SH-SY5Y cells with CBE resulted
in increased levels of SNCA (Manning-Bog et al. 2009;
Cleeter et al. 2013). Single injection of CBE led to about
20% increase in SNCA levels in the ventral mesencephalon
of normal mice. Also, enhanced SNCA immunoreactivity
was observed within the cell bodies of the substantia nigra
pars compacta and within the cytoplasm and cell nuclei of
A9 neurons of CBE-treated mice (Manning-Bog et al. 2009).
Finally, SNCA accumulation and SNCA oligomer formation
was shown in a mouse model carrying homozygous knock-
out of Gba1, i.e. in mice modeling loss-of-function of GCase
(Osellame et al. 2013).
The third hypothesis proposes the existence of a bidirec-
tional feedback loop in which GCase deﬁciency facilitates
formation of alpha-synuclein oligomers, with the subsequent
increase in alpha-synuclein oligomers leading to further
decrease in normal GCase activity, which in turn promotes
formation of additional alpha-synuclein oligomers (Mazzulli
et al. 2011). It has also been demonstrated in cell models that
increased alpha-synuclein causes a decrease in GCase
activity and protein levels, as over-expression of exogenous
SNCA in SH-SY5Y cell lines resulted in about 44–70%
decrease in GCase activity, and about 33–87% decrease in
GCase protein levels (Gegg et al. 2012).
Finally, although a majority of the studies conducted to
date provide a link between GCase and SNCA via loss-,
gain-of function, or bidirectional feedback loop, some studies
failed to support the relationship between SNCA and mutant
GCase. The ﬁrst such study showed that GBA1 inhibition by
CBE in both differentiated SH-SY5Y cells and rat cortical
neuronal cultures did not signiﬁcantly increase SNCA
accumulation (Dermentzaki et al. 2013). This contradicts
the results obtained by others, which showed an increase in
SNCA levels in CBE-treated differentiated SH-SY5Y cells
(Manning-Bog et al. 2009; Cleeter et al. 2013). This differ-
ence may simply have been due to the shorter exposure in the
Dermentzaki study. The second such study demonstrated that
GBA1 inhibition by CBE in PC12 cell line did not alter
SNCA levels, and that over-expression of human wild-type
GBA1 did not lead to an increase in SNCA levels in neural
MES23.5 cell line. The same study, however, showed that
over-expression of wild-type GBA1 in HEK293-SNCA
[A53T] and PC12 cell lines resulted in decrease of SNCA
levels, and that over-expression of different mutant GCase in
MES23.6 and PC12 cells led to a signiﬁcant increase in
SNCA levels (Cullen et al. 2011). The cell model speciﬁcity
might explain the observed discrepancy in the effect of over-
expression of wild-type GBA1 on SNCA levels.
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Altogether, although convincing evidence supporting the
relationship between SNCA and both gain- and loss-of-
function of mutant GCase exists, neither of them explains
why only a proportion of individuals with GBA1 mutations
develop PD. One plausible explanation might be that in order
to develop PD-GBA1, in addition to the GBA1 mutation,
there must be additional genetic alternations. Another
credible explanation might be that mutated GCase on its
own is not sufﬁcient to induce alpha-synuclein pathology:
perhaps only when other changes occur (e.g. a perturbation
of a component of the lysosomal degradation pathway
resulting in defective SNCA clearance) can PD-GBA1
develop.
GCase and mitochondria
Mitochondria not only play a central role in energy production
by oxidative phosphorylation but are also involved in many
other cellular processes, such as synthesis of steroids and
regulation of calcium homeostasis, membrane potential,
apoptosis, and stress response. Taking into account the
plethora of mitochondrial functions, perhaps not surprisingly,
mitochondrial impairment plays an important role in the
pathogenesis of PD (Schapira et al. 1989, 1990). In neurons,
mechanistically, accumulation of dysfunctional mitochondria
results in generation of reactive oxygen species and free
radicals leading eventually to neuronal death. Mutations in
PARK2, PINK1, and Parkinson protein 7 (PARK7 or DJ-1)
genes, which affect mitochondrial morphology and function,
have been identiﬁed as causing familial PD (Schapira 2008).
However, the role of mitochondrial dysfunction in the
pathogenesis of PD-GBA1 remains elusive and, to date, only
three studies have investigated the impact of GBA1 mutations
on mitochondrial function. The ﬁrst study showed that
inhibition of GBA1 by CBE in SHSY-5Y cells led to a
decrease in adenosine diphosphate phosphorylation, decline in
mitochondrial membrane potential, and increase in free radical
generation, so demonstrating that GCase loss-of-function
causes oxidative stress andmitochondrial dysfunction (Cleeter
et al. 2013). The second study showed that loss-of-function of
GCase in a mouse model carrying homozygous knock-out of
GBA1 resulted in accumulation of dysfunctional and frag-
mented mitochondria, and reduction in respiratory chain
complex activities, membrane potential, and oxygen con-
sumption (Osellame et al. 2013). The third study showed that
gain-of-function of GCase in hypomorphic prosaposin mice
carrying homozygous D409H or V394LGba1mutation led to
signiﬁcant reduction in oxygen consumption and mitochon-
drial adenosine triphosphate (ATP) production. The same
ﬁndings were also observed in wild-type cerebral cortical
neural cells treated with CBE (Xu et al. 2014). Altogether,
data from cell and animalmodel studies demonstrated that both
loss- and gain-of-function GBA1 mutations cause mitochon-
drial impairment, and so it would be worth investigating
whether mitochondrial dysfunction is also present in
PD-GBA1 brains.
GCase and autophagy
Autophagy is a lysosomal pathway that is involved in
degradation of damaged organelles, such as mitochondria
and endoplasmic reticulum, and clearance of long-lived
misfolded or aggregated proteins, such as alpha-synuclein.
Three distinct types of autophagy have been identiﬁed:
macroautophagy, microautophagy, and chaperone-mediated
autophagy (CMA). Increasing evidence indicates the exis-
tence of a strong link between impairment of autophagy and
PD. Dysfunction of autophagy has been shown both in brain
tissue samples from idiopathic PD patients and toxic mouse
models of PD (Chu et al. 2009; Alvarez-Erviti et al. 2010;
Dehay et al. 2010; Vila et al. 2011). Although involvement
of autophagic impairment in the development of GD and
especially PD is not yet fully understood, emerging data
clearly suggest its importance.
Lysosomal dysfunction resulting in progressive accu-
mulation of glucocerebroside plays a central role in GD
pathogenesis. Accumulation of sphingolipids, to which
glucocerebroside belongs, has been shown to alter autophagy
by both inducing cell death and reducing autophagosome
clearance, and so promoting their accumulation (Tamboli
et al. 2011). Indeed, induction of autophagy has been demon-
strated in GD human ﬁbroblasts that showed accumulation of
glucocerebroside, while increased number of autophagosomes
has been shown in hypomorphic prosaposin mice carrying the
homozygous V394L Gba1 mutation that showed accumula-
tion of glucocerebroside (Sun et al. 2010a,b; Vaccaro et al.
2010). However, it seems unlikely that the autophagic
dysfunction in PD-GBA1 is because of accumulation of
glucocerebroside (and glucosphingosine, a deacetylated glu-
cocerebroside), since substrate accumulation is believed to
require bothGBA1 alleles to carry a genetic alteration, and this
is not the case in the majority of PD-GBA1 individuals.
Analysis of putamen and cerebellum samples from PD-GBA1
patients supports that notion, as no accumulation of gluco-
cerebroside and glucosphingosine was observed in these brain
regions (Gegg et al. 2015). In contrast, signiﬁcantly increased
glucosphingosine levels (and signiﬁcantly reduced GCase
activity) were detected in the substantia nigra and hippocam-
pus of idiopathic PD patients during sixth and seventh decade
of life, respectively (Rocha et al. 2015). However, no changes
in glucosphingosine levels were observed in the putamen and
cerebellum of idiopathic PD patients, although a signiﬁcant
reduction in GCase activity was observed in these regions
(Gegg et al. 2015; Rocha et al. 2015). The observed discrep-
ancy in glucosphingosine accumulation among different brain
regions should prompt further analysis in both of PD-GBA1
and idiopathic PD patients to establishwhether the relationship
between reduction of GCase activity and accumulation of
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glucosphingosine exists, and, if indeed there is such a link
whether autophagic dysfunction should be at least partially
attributed to GCase substrate accumulation.
The relationship between SNCA and both gain- and loss-of-
function of mutant GCase provides a plausible explanation
linking autophagic impairment with PD-GBA1. It has been
shown that SNCA is preferentially degraded by CMA, and that
impairment of CMA leads to accumulation and aggregation of
SNCA in SH-SY5Y cell lines (Alvarez-Erviti et al. 2010).
Conversely, it has been demonstrated that expression ofmutant
SNCA leads to CMA impairment in proliferating PC12 and
SH-SY5Y cells, while over-expression of wild-type SNCA
results in CMA dysfunction in differentiated SH-SY5Y cells
(Xilouri et al. 2009). The latter observation is especially
interesting, as misfolded GCase has been shown to facilitate
SNCA accumulation and aggregation (Mazzulli et al. 2011;
Westbroek et al. 2011; Sidransky and Lopez 2012), and so it
can be speculated that SNCA increase because of GCase
dysfunction might lead to CMA impairment. Thus, ﬁnding a
therapeutic agent that is able to increase levels of functional,
properly folded GCase would enhance SNCA degradation by
CMA, and consequently lead to reduction in SNCA levels.
GCase and endoplasmic reticulum stress
Secretory and membrane-associated proteins are synthetized
in the endoplasmic reticulum and newly synthetized proteins
are folded in the ER with the help of ER chaperones. Proteins
that fail to fold correctly are recognized by the ER quality
control system and retained for refolding. Misfolded proteins
that fail to refold by ER chaperones are disposed of by
ERAD via the ubiquitin–proteasome system. When the
number of misfolded proteins exceeds the capacity of the
ERAD system, misfolded proteins accumulate in the ER
causing stress. In response to such stress, the unfolded
protein response (UPR) is activated to help restore normal
cell function. If this fails, and ER stress continues, malfunc-
tioning cells are eliminated by apoptosis (Yoshida 2007).
Emerging evidence shows the involvement of ER stress in
the pathogenesis of PD (Imai et al. 2001; Ryu et al. 2002).
The direct link between ER stress and PD comes from studies
of parkin (PARK2), which in mutated form causes early
onset of PD. Parkin, an E3 ubiquitin ligase is a member of
the UPR, where it is responsible for ubiquitination of
misfolded proteins for degradation. Clearance of misfolded
proteins is impaired when parkin is mutated, which eventu-
ally results in ER stress (Imai et al. 2000, 2001). The link
between misfolded GCase and ER stress is very plausible, as
prolonged accumulation of misfolded GCase in the ER
would eventually cause ER stress and UPR activation.
Misfolded GCases, including N370S and L444P mutants,
have been shown to be retained in the ER and undergo
ERAD in human GD ﬁbroblasts (Ron and Horowitz 2005;
Bendikov-Bar et al. 2011). Moreover, it has been reported
that GD severity shows correlation with levels of misfolded
GCase retention in the ER and so, speculatively, with ER
stress (Ron and Horowitz 2005). Biochemical analysis of
PD-GBA1 putamen samples for the presence of UPR markers
showed a 63% increase in C/EBP homologous protein levels
and a 26% increase in binding immunoglobulin protein. The
observed UPR/ERAD could be caused by misfolded GCase,
but other causes such as oxidative stress, mitochondrial
dysfunction, proteolysis, or altered calcium homeostasis
cannot be excluded (Gegg et al. 2012). The direct interaction
of misfolded GCase with parkin, and its subsequent ERAD
degradation, has been observed in human COS7 and
HEK293 cells, providing evidence for the existence of a
direct link between PD-GBA1 and ERAD. Misfolded GCase-
parkin interaction can block parkin interaction with other
protein that are degraded via parkin-mediated ERAD, which
would result in further accumulation of proteins in the ER
and a further increase in ER stress that would consequently
result in neuronal death, and so PD development (Ron et al.
2010). In contrast to human studies, analysis of UPR markers
in the neuronal cultures and tissues obtained from transgenic
GD mouse models and CBE-treated normal mice showed no
alternations in C/EBP homologous protein, binding
immunoglobulin protein, and X-box binding protein 1
(XBP1) (Farfel-Becker et al. 2009). Further studies are
required to establish whether ER stress really contributes to
the pathogenesis of PD-GBA1.
PD-GBA1 treatment
There is no speciﬁc treatment available for PD-GBA1 patients
to modify the course of the disease. Since nigral dopamine loss
observed in individuals with PD-GBA1 is identical to that
observed in individuals with idiopathic PD, PD-GBA1 patients
are normally given dopaminergic therapy to alleviate the
dopamine deﬁcit in the striatum. Therefore, the development
of new therapies that can slow down disease progression is
urgently required. The increasing evidence linkingGCasewith
alpha-synuclein and mitochondrial pathways has relevance to
a potential novel therapeutic strategy for both PD-GBA1 and
idiopathic PD patients.Moreover, even patients withoutGBA1
mutations show signiﬁcant reduction in GCase activity in the
substantia nigra (Gegg et al. 2012). This highlights the
importance of GCase function, not only in PD-GBA1 but also
in idiopathic PD and suggests that GBA1 treatments may
potentially prove to be effective with many, if not all, PD
patients (Schapira andGegg 2013). The use of small molecular
chaperones such as N-(n-nonyl)deoxynojirimycin, isofago-
mine, pyrazolopyrimidines, or ambroxol (i.e. the same chap-
erones that are currently being tested for their application in
treating GD) may be of interest as a novel therapy for PD, as a
means to decrease alpha-synuclein levels and improve mito-
chondrial function (Sawkar et al. 2002; Steet et al. 2006;
Maegawa et al. 2009; Bendikov-Bar et al. 2011, 2013;
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Patnaik et al. 2012; Luan et al. 2013; Sanders et al. 2013;
McNeill et al. 2014). Interestingly, the beneﬁts of increasing
wild-type GCase stability, trafﬁcking, and activity in idio-
pathic PD have been demonstrated through the study of mice
over-expressing human alpha-synuclein under the murine
Thy-1 promoter (Thy1-aSyn). Administration of a molecular
chaperone AT2101 (afegostat-tartrate, isofagomine) led to
GCase increase in the brain and resulted in improvement of
both motor function and neuropathological manifestations
(such as elimination of microglial inﬂammatory response and
reduction in alpha-synuclein immunoreactivity in the substa-
nia nigra) in Thy1-aSyn mice (Richter et al. 2014). These
results show that an increase in GCase activity achieved by
administration of molecular chaperones might signiﬁcantly
improve clinical and biochemical manifestations of synucle-
inopathies, even those without GBA1 mutations, and so
further development of small molecular chaperones gives a
great promise for ﬁnding a successful treatment not only for
PD-GBA1, but also for idiopathic PD and other synucle-
inopathies.
Conclusions
After Alzheimer, Parkinson disease is the second most
common neurodegenerative disorder. The most common
risk factor for PD involves mutations in the GBA1 gene,
which occurs in 5–10% of PD patients (Sidransky et al.
2009; Bultron et al. 2010; McNeill et al. 2012a). This
compares with leucine-rich repeat kinase 2 mutations that
are estimated to cause 0.5% of sporadic PD. Further, even
in patients without GBA1 mutations, a decrease in GCase
activity is still found in all studied cases, suggesting that
this protein plays a much more important role in PD than
previously appreciated. As such, further studies of GBA1, in
particular of treatments that increase levels of GCase, are
likely to be one of the most promising future avenues for
tackling PD.
Acknowledgments and conflict of interest
disclosure
This work was supported by the Medical Research Council (MRC)
grant (MR/M006646/1), Javon Trust grant, Parkinson’s UK (PUK)
grant (G1403) and National Institute of Healthcare Research (NIHR)
grant (RCF30AS2012, RCF73TS20145989 and RCF103/AS/2014).
AHVS is a National Institute of Healthcare Research (NIHR) Senior
Investigator. The authors declare that there are no conﬂicts of
interest.
References
Aharon-Peretz J., Rosenbaum H. and Gershoni-Baruch R. (2004)
Mutations in the glucocerebrosidase gene and Parkinson’s
disease in Ashkenazi Jews. N. Engl. J. Med. 351, 1972–1977.
Alvarez-Erviti L., Rodriguez-Oroz M. C., Cooper J. M., Caballero C.,
Ferrer I., Obeso J. A. and Schapira A. H. (2010) Chaperone-
mediated autophagy markers in Parkinson disease brains. Arch.
Neurol. 67, 1464–1472.
Angeli A., Mencacci N. E., Duran R. et al. (2013) Genotype and
phenotype in Parkinson’s disease: lessons in heterogeneity from
deep brain stimulation. Mov. Disord. 28, 1370–1375.
Asselta R., Rimoldi V., Siri C., Cilia R., Guella I., Tesei S., Solda G.,
Pezzoli G., Duga S. and Goldwurm S. (2014) Glucocerebrosidase
mutations in primary parkinsonism. Parkinsonism Relat. Disord.
20, 1215–1220.
Beavan M., McNeill A., Proukakis C., Hughes D. A., Mehta A. and
Schapira A. H. (2015) Evolution of prodromal clinical markers of
Parkinson disease in a GBA mutation-positive cohort. JAMA
Neurol. 72, 201–208.
Bembi B., Zambito Marsala S., Sidransky E., Ciana G., Carrozzi M.,
Zorzon M., Martini C., Gioulis M., Pittis M. G. and Capus L.
(2003) Gaucher’s disease with Parkinson’s disease: clinical and
pathological aspects. Neurology 61, 99–101.
Bendikov-Bar I., Ron I., Filocamo M. and Horowitz M. (2011)
Characterization of the ERAD process of the L444P mutant
glucocerebrosidase variant. Blood Cells Mol. Dis. 46, 4–10.
Bendikov-Bar I., Maor G., Filocamo M. and Horowitz M. (2013)
Ambroxol as a pharmacological chaperone for mutant
glucocerebrosidase. Blood Cells Mol. Dis. 50, 141–145.
Bennett L. L. and Mohan D. (2013) Gaucher disease and its treatment
options. Ann. Pharmacother. 47, 1182–1193.
Berg-Fussman A., Grace M. E., Ioannou Y. and Grabowski G. A. (1993)
Human acid beta-glucosidase. N-glycosylation site occupancy and
the effect of glycosylation on enzymatic activity. J. Biol. Chem.
268, 14861–14866.
Bernier V., Lagace M., Bichet D. G. and Bouvier M. (2004)
Pharmacological chaperones: potential treatment for
conformational diseases. Trends Endocrinol. Metab. 15, 222–228.
Beutler E. (1992) Gaucher disease: new molecular approaches to
diagnosis and treatment. Science 256, 794–799.
Beutler E. and Grabowski G. A. (2001) Glucosylceramide lipidosis–
Gaucher disease, in The metabolic and molecular bases of
inherited diseases, 8th edn (Scriver C. R., Beaudet A. L., Sly W.
S. and Valle D., eds), pp. 3635–3668. McGraw-Hill, New York.
Bras J., Paisan-Ruiz C., Guerreiro R., Ribeiro M. H., Morgadinho A.,
Januario C., Sidransky E., Oliveira C. and Singleton A. (2009)
Complete screening for glucocerebrosidase mutations in Parkinson
disease patients from Portugal. Neurobiol. Aging 30, 1515–1517.
Brockmann K., Srulijes K., Hauser A. K., Schulte C., Csoti I., Gasser T.
and Berg D. (2011) GBA-associated PD presents with nonmotor
characteristics. Neurology 77, 276–280.
Bronstein S., Karpati M. and Peleg L. (2014) An update of Gaucher
mutations distribution in the Ashkenazi Jewish population:
prevalence and country of origin of the mutation R496H. Isr.
Med. Assoc. J. 16, 683–685.
Bultron G., Kacena K., Pearson D., Boxer M., Yang R., Sathe S.,
Pastores G. and Mistry P. K. (2010) The risk of Parkinson’s disease
in type 1 Gaucher disease. J. Inherit. Metab. Dis. 33, 167–173.
Choi J. M., Kim W. C., Lyoo C. H. et al. (2012) Association of
mutations in the glucocerebrosidase gene with Parkinson disease in
a Korean population. Neurosci. Lett. 514, 12–15.
Chu Y., Dodiya H. A., Ebischer P. O., lanow C. W. and Kordower J. H.
(2009) Alterations in lysosomal and proteasomal markers in
Parkinson’s disease: relationship to alpha-synuclein inclusions.
Neurobiol. Dis. 35, 385–398.
Clark L. N., Ross B. M., Wang Y., Mejia-Santana H., Harris J., Louis E.
D., Cote L. J., Andrews H., Fahn S., Waters C., Ford B., Frucht S.,
Ottman R. and Marder K. (2007) Mutations in the
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
International Society for Neurochemistry, J. Neurochem. (2016) 139 (Suppl. 1), 77--90
The relationship between GBA1 mutations and PD 87
glucocerebrosidase gene are associated with early-onset Parkinson
disease. Neurol. 69, 1270–1277.
Clark L. N., Kartsaklis L. A., Wolf Gilbert R. et al. (2009) Association
of glucocerebrosidase mutations with dementia with Lewy bodies.
Arch. Neurol. 66, 578–583.
Cleeter M. W., Chau K. Y., Gluck C., Mehta A., Hughes D. A., Duchen
M., Wood N. W., Hardy J., Mark Cooper J. and Schapira A. H.
(2013) Glucocerebrosidase inhibition causes mitochondrial
dysfunction and free radical damage. Neurochem. Int. 62, 1–7.
Cormand B., Montfort M., Chabas A., Vilageliu L. and Grinberg D.
(1997) Genetic ﬁne localization of the beta-glucocerebrosidase
(GBA) and prosaposin (PSAP) genes: implications for Gaucher
disease. Hum. Genet. 100, 75–79.
Cox T. M. and Schoﬁeld J. P. (1997) Gaucher’ s disease: clinical features
and natural history. Baillieres Clin. Haematol. 10, 657–689.
Cullen V., Sardi S. P., Ng J. et al. (2011) Acid b-glucosidase mutants
linked to Gaucher disease, Parkinson disease, and Lewy body
dementia alter a-synuclein processing. Ann. Neurol. 69, 940–953.
De Marco E. V., Annesi G., Tarantino P. et al. (2008)
Glucocerebrosidase gene mutations are associated with
Parkinson’s disease in southern Italy. Mov. Disord. 23, 460–463.
Dehay B., Bove J., Rodrıguez-Muela N., Perier C., Recasens A., Boya P.
and Vila M. (2010) Pathogenic lysosomal depletion in Parkinson ‘
s disease. J. Neurosci. 30, 12535–12544.
Dermentzaki G., Dimitriou E., Xilouri M., Michelakakis H. and Stefanis
L. (2013) Loss of b-glucocerebrosidase activity does not affect
alpha-synuclein levels or lysosomal function in neuronal cells.
PLoS ONE 8, e60674.
Dvir H., Harel M., McCarthy A. A., Toker L., Silman I., Futerman A. H.
and Sussman J. L. (2003) X-ray structure of human acid-beta-
glucosidase, the defective enzyme in Gaucher disease. EMBO Rep.
4, 704–709.
Emelyanov A., Boukina T., Yakimovskii A., Usenko T., Drosdova A.,
Zakharchuk A., Andoskin P., Dubina M., Schwarzman A. and
Pchelina S. (2012) Glucocerebrosidase gene mutations are
associated with Parkinson’s disease in Russia. Mov. Disord. 27,
158–159.
Enquist I. B., Lo Bianco C., Ooka A., Nilsson E., Mansson J. E., Ehinger
M., Richter J., Brady R. O., Kirik D. and Karlsson S. (2007)
Murine models of acute neuronopathic Gaucher disease. Proc. Natl
Acad. Sci. USA 104, 17483–17488.
Farfel-Becker T., Vitner E., Dekel H., Leshem N., Enquist I. B.,
Karlsson S. and Futerman A. H. (2009) No evidence for activation
of the unfolded protein response in neuronopathic models of
Gaucher disease. Hum. Mol. Genet. 18, 1482–1488.
Gan-Or Z., Giladi N., Rozovski U., Shifrin C., Rosner S., Gurevich T.,
Bar-Shira A. and Orr-Urtreger A. (2008) Genotype-phenotype
correlations between GBA mutations and Parkinson disease risk
and onset. Neurology 70, 2277–2283.
Gaucher P. C. E. (1882) De l’ epithelioma primitif de la rate,
hypertrophie idiopathique de la rate sans leucemie. Academic
thesis. Paris, France.
GeggM.E., BurkeD.,Heales S. J., Cooper J.M., Hardy J.,WoodN.W. and
Schapira A. H. (2012) Glucocerebrosidase deﬁciency in substantia
nigra of parkinson disease brains. Ann. Neurol. 72, 455–463.
Gegg M. E., Sweet L., Wang B. H., Shihabuddin L. S., Sardi S. P. and
Schapira A. H. V. (2015) No evidence for substrate accumulation
in Parkinson brains with GBA mutations. Mov. Disord. 30, 1085–
1089.
Goker-Alpan O., Schiffmann R., Lamarca M. E., Nussbaum R. L.,
Mcinerney-Leo A. and Sidransky E. (2004) Parkinsonism among
Gaucher disease carriers. J. Med. Genet. 41, 937–940.
Goker-Alpan O., Lopez G., Vithayathil J., Davis J., Hallett M. and
Sidransky E. (2008) The spectrum of parkinsonian manifestations
associated with glucocerebrosidase mutations. Arch. Neurol. 65,
1353–1357.
Goker-Alpan O., Stubbleﬁeld B. K., Giasson B. I. and Sidransky E.
(2010) Glucocerebrosidase is present in a-synuclein inclusions in
Lewy body disorders. Acta Neuropathol. 120, 641–649.
Goker-Alpan O., Masdeu J. C., Kohn P. D. et al. (2012) The
neurobiology of glucocerebrosidase-associated parkinsonism: a
positron emission tomography study of dopamine synthesis and
regional cerebral blood ﬂow. Brain 135, 2440–2448.
Gonzalez-Del Rincon Mde L., Monroy Jaramillo N., Suarez Martınez A.
I., Yescas Gomez P., Boll Woehrlen M. C., Lopez Lopez M. and
Alonso Vilatela M. E. (2013) The L444P GBA mutation is
associated with early-onset Parkinson’s disease in Mexican
Mestizos. Clin. Genet. 84, 386–387.
Grabowski G. A. (2008) Phenotype, diagnosis, and treatment of
Gaucher’s disease. Lancet 372, 1263–1271.
Halperin A., Elstein D. and Zimran A. (2006) Increased incidence of
Parkinson disease among relatives of patients with Gaucher
disease. Blood Cells Mol. Dis. 36, 426–428.
Horowitz M., Wilder S., Horowitz Z., Reiner O., Gelbart T. and Beutler
E. (1989) The human glucocerebrosidase gene and pseudogene:
structure and evolution. Genomics 4, 87–96.
Hruska K. S., LaMarca M. E., Scott C. R. and Sidransky E. (2008)
Gaucher disease: mutation and polymorphism spectrum in the
glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567–583.
Hu F. Y., Xi J., Guo J., Yu L. H., Liu L., He X. H., Liu Z. L., Zou X. Y.
and Xu Y. M. (2010) Association of the glucocerebrosidase N370S
allele with Parkinson’s disease in two separate Chinese Han
populations of mainland China. Eur. J. Neurol. 17, 1476–1478.
Huang C. L., Wu-Chou Y. H., Lai S. C., Chang H. C., Yeh T. H., Weng
Y. H., Chen R. S., Huang Y. Z. and Lu C. S. (2011) Contribution
of glucocerebrosidase mutation in a large cohort of sporadic
Parkinson’s disease in Taiwan. Eur. J. Neurol. 18, 1227–1232.
Imai Y., Soda M. and Takahashi R. (2000) Parkin suppresses unfolded
protein stress-induced cell death through its E3 ubiquitin-protein
ligase activity. J. Biol. Chem. 205, 35661–35664.
Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y. and Takahashi R.
(2001) An unfolded putative transmembrane polypeptide, which
can lead to endoplasmic reticulum stress, is a substrate of Parkin.
Cell 105, 891–902.
Jovic M., Kean M. J., Szentpetery Z., Polevoy G., Gingras A. C., Brill J.
A. and Balla T. (2012) Two phosphatidylinositol 4-kinases control
lysosomal delivery of the Gaucher disease enzyme, beta-
glucocerebrosidase. Mol. Biol. Cell 23, 1533–1545.
Kalinderi K., Bostantjopoulou S., Paisan-Ruiz C., Katsarou Z., Hardy J.
and Fidani L. (2009) Complete screening for glucocerebrosidase
mutations in Parkinson disease patients from Greece. Neurosci.
Lett. 452, 87–89.
Kumar K. R., Ramirez A., G€obel A. et al. (2013) Glucocerebrosidase
mutations in a Serbian Parkinson’s disease population. Eur. J.
Neurol. 20, 402–405.
Lesage S. and Brice A. (2009) Parkinson’s disease: from monogenic
forms to genetic susceptibility factors. Hum. Mol. Genet. 18, R48–
R59.
Lesage S., Anheim M., Condroyer C. et al. ; French Parkinson’s Disease
Genetics Study Group (2011) Large-scale screening of the
Gaucher’s disease-related glucocerebrosidase gene in Europeans
with Parkinson’s disease. Hum. Mol. Genet. 20, 202–210.
Luan Z., Li L., Higaki K., Nanba E., Suzuki Y. and Ohno K. (2013) The
chaperone activity and toxicity of ambroxol on Gaucher cells and
normal mice. Brain Dev. 35, 317–322.
Lwin A., Orvisky E., Goker-Alpan O., Lamarca M. E. and Sidransky E.
(2004) Glucocerebrosidase mutations in subjects with
parkinsonism. Mol. Genet. Metab. 81, 70–73.
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
International Society for Neurochemistry, J. Neurochem. (2016) 139 (Suppl. 1), 77--90
88 A. Migdalska-Richards and A. H. V. Schapira
Maegawa G. H., Tropak M. B., Buttner J. D. et al. (2009) Identiﬁcation
and characterization of ambroxol as an enzyme enhancement agent
for Gaucher disease. J. Biol. Chem. 284, 23502–23516.
Manning-Bog A. B., Sch€ule B. and Langston J. W. (2009) Alpha-
synuclein-glucocerebrosidase interactions in pharmacological
Gaucher models: a biological link between Gaucher disease and
parkinsonism. Neurotoxicology 30, 1127–1132.
Mao X. Y., Burgunder J. M., Zhang Z. J., An X. K., Zhang J. H., Yang
Y., Li T., Wang Y. C., Chang X. L. and Peng R. (2010)
Association between GBA L444P mutation and sporadic
Parkinson’s disease from Mainland China. Neurosci. Lett. 469,
256–259.
Mata I. F., Samii A., Schneer S. H. et al. (2008) Glucocerebrosidase
gene mutations: a risk factor for Lewy body disorders. Arch.
Neurol. 65, 379–382.
Mazzulli J. R., Xu Y. H., Sun Y., Knight A. L., McLean P. J., Caldwell G.
A., Sidransky E., Grabowski G. A. and Krainc D. (2011) Gaucher
disease glucocerebrosidase and a-synuclein form a bidirectional
pathogenic loop in synucleinopathies. Cell 146, 37–52.
McKeran R. O., Bradbury P., Taylor D. and Stern G. (1985)
Neurological involvement of type 1 (adult) Gaucher’s disease. J.
Neurol. Neurosurg. Psychiatry 48, 172–175.
McNeill A., Duran R., Hughes D. A., Mehta A. and Schapira A. H.
(2012a) A clinical and family history study of Parkinson’s disease
in heterozygous glucocerebrosidase mutation carriers. J. Neurol.
Neurosurg. Psychiatry 83, 853–854.
McNeill A., Duran R., Proukakis C., Bras J., Hughes D., Mehta A.,
Hardy J., Wood N. W. and Schapira A. H. (2012b) Hyposmia and
cognitive impairment in Gaucher disease patients and carriers.
Mov. Disord. 27, 526–532.
McNeill A., Roberti G., Lascaratos G., Hughes D., Mehta A., Garway-
Heath D. F. and Schapira A. H. (2013a) Retinal thinning in
Gaucher disease patients and carriers: results of a pilot study. Mol.
Genet. Metab. 109, 221–223.
McNeill A., Wu R. M., Tzen K. Y. et al. (2013b) Dopaminergic
neuronal imaging in genetic Parkinson’s disease: insights into
pathogenesis. PLoS ONE 8, e69190.
McNeill A., Magalhaes J., Shen C. et al. (2014) Ambroxol improves
lysosomal biochemistry in glucocerebrosidase mutation-linked
Parkinson disease cells. Brain 137, 1481–1495.
Moraitou M., Hadjigeorgiou G., Monopolis I. et al. (2011) b-
glucocerebrosidase gene mutations in two cohorts of Greek
patients with sporadic Parkinson’s disease. Mol. Genet. Metab.
104, 149–152.
National Organization of Rare Disorders (2013) Gaucher disease. http://
www.rarediseases.org/rare-disease-information/rarediseases/byID/
12/viewFullReport. [accessed on July 25, 2013].
Neumann J., Bras J., Deas E. et al. (2009) Glucocerebrosidase mutations
in clinical and pathologically proven Parkinson’s disease. Brain
132, 1783–1794.
Osellame L. D., Rahim A. A., Hargreaves I. P., Gegg M. E., Richard-
Londt A., Brandner S., Waddington S. N., Schapira A. H. and
Duchen M. R. (2013) Mitochondria and quality control defects in a
mouse model of Gaucher disease — links to Parkinson’s disease.
Cell Metab. 17, 941–953.
Patnaik S., Zheng W., Choi J. H. et al. (2012) Discovery, structure-
activity relationship, and biological evaluation of noninhibitory
small molecule chaperones of glucocerebrosidase. J. Med. Chem.
55, 5734–5748.
Pulkes T., Choubtum L., Chitphuk S., Thakkinstian A., Pongpakdee S.,
Kulkantrakorn K., Hanchaiphiboolkul S., Tiamkao S. and
Boonkongchuen P. (2014) Glucocerebrosidase mutations in Thai
patients with Parkinson’s disease. Parkinsonism Relat. Disord. 20,
986–991.
Reczek D., Schwake M., Schroder J., Hughes H., Blanz J., Jin X.,
Brondyk W., Van Patten S., Edmunds T. and Saftig P. (2007)
LIMP-2 is a receptor for lysosomal mannose-6-phosphate-
independent targeting of beta-glucocerebrosidase. Cell 131, 770–
783.
Richter F., Fleming S. M., Watson M. et al. (2014) A GCase chaperone
improves motor function in a mouse model of synucleinopathy.
Neurotherapeutics 11, 840–856.
Rocha E. M., Smith G. A., Park E., Cao H., Brown E., Hallett P. and
Isacson O. (2015) Progressive decline of glucocerebrosidase in
aging and Parkinson's disease. Ann. Clin. Transl. Neurol. 2, 433–
438.
Ron I. and Horowitz M. (2005) ER retention and degradation as the
molecular basis underlying Gaucher disease heterogeneity. Hum.
Mol. Genet. 14, 2387–2398.
Ron I., Rapaport D. and Horowitz M. (2010) Interaction between parkin
and mutant glucocerebrosidase variants: a possible link between
Parkinson disease and Gaucher disease. Hum. Mol. Genet. 19,
3771–3781.
Ryu E. J., Harding H. P., Angelastro J. M., Vitolo O. V., Ron D. and
Greene L. A. (2002) Endoplasmic reticulum stress and the
unfolded protein response in cellular models of Parkinson’s
disease. J. Neurosci. 22, 10690–10698.
Sanders A., Hemmelgarn H., Melrose H. L., Hein L., Fuller M. and
Clarke L. A. (2013) Transgenic mice expressing human
glucocerebrosidase variants: utility for the study of Gaucher
disease. Blood Cells Mol. Dis. 51, 109–115.
Sardi S. P., Clarke J., Viel C. et al. (2013) Augmenting CNS
glucocerebrosidase activity as a therapeutic strategy for
parkinsonism and other gaucher-related synucleinopathies. Proc.
Natl Acad. Sci. USA 110, 3537–3542.
Sato C., Morgan A., Lang A. E., Salehi-Rad S., Kawarai T., Meng Y.,
Ray P. N., Farrer L. A., St George-Hyslop P. and Rogaeva E.
(2005) Analysis of the glucocerebrosidase gene in Parkinson’s
disease. Mov. Disord. 20, 367–370.
Sawkar A. R., Cheng W. C., Beutler E., Wong C. H., Balch W. E.
and Kelly J. W. (2002) Chemical chaperones increase the
cellular activity of N370S beta-glucosidase: a therapeutic
strategy for Gaucher disease. Proc. Natl Acad. Sci. USA 99,
15428–15433.
Schapira A. H. (2008) Mitochondria in the aetiology and pathogenesis of
Parkinson’s disease. Lancet Neurol. 7, 97–109.
Schapira A. H. and Gegg M. E. (2013) Glucocerebrosidase in the
pathogenesis and treatment of Parkinson disease. Proc. Natl Acad.
Sci. USA 110, 3214–3215.
Schapira A. H. and Tolosa E. (2010) Molecular and clinical prodrome of
Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6,
309–317.
Schapira A. H., Cooper J. M., Dexter D., Jenner P., Clark J. B. and
Marsden C. D. (1989) Mitochondrial complex I deﬁciency in
Parkinson’s disease. Lancet 1, 1269.
Schapira A. H., Cooper J. M., Dexter D., Clark J. B., Jenner P. and
Marsden C. D. (1990) Mitochondrial complex I deﬁciency in
Parkinson’s disease. J. Neurochem. 54, 823–827.
Seto-Salvia N., Pagonabarraga J., Houlden H. et al. (2012)
Glucocerebrosidase mutations confer a greater risk of dementia
during Parkinson’s disease course. Mov. Disord. 27, 393–399.
Sidransky E. (2012) Gaucher disease: insights from a rare Mendelian
disorder. Discov. Med. 14, 273–281.
Sidransky E. and Lopez G. (2012) The link between the GBA gene and
parkinsonism. Lancet Neurol. 11, 986–998.
Sidransky E., Nalls M. A., Aasly J. O. et al. (2009) Multicenter analysis
of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J.
Med. 361, 1651–1661.
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
International Society for Neurochemistry, J. Neurochem. (2016) 139 (Suppl. 1), 77--90
The relationship between GBA1 mutations and PD 89
Sorge J., West C., Westwood B. and Beutler E. (1985) Molecular
cloning and nucleotide sequence of human glucocerebrosidase
cDNA. Proc. Natl Acad. Sci. USA 82, 7289–7293.
Sorge J., Kuhl W., West C. and Beutler E. (1987a) Complete correction
of the enzymatic defect of type I Gaucher disease ﬁbroblasts by
retroviral-mediated gene transfer. Proc. Natl Acad. Sci. USA 84,
906–909.
Sorge J. A., West C., Kuhl W., Treger L. and Beutler E. (1987b) The
human glucocerebrosidase gene has two functional ATG initiator
codons. Am. J. Hum. Genet. 41, 1016–1024.
Sorge J., Gross E., West C. and Beutler E. (1990) High level
transcription of the glucocerebrosidase pseudogene in normal
subjects and patients with Gaucher disease. J. Clin. Invest. 86,
1137–1141.
Spitz M., Rozenberg R., Pereira Lda. V. and Reis Barbosa E. (2008)
Association between Parkinson’s disease and glucocerebrosidase
mutations in Brazil. Parkinsonism Relat. Disord. 14, 58–62.
Steet R. A., Chung S., Wustman B., Powe A., Do H. and Kornfeld S. A.
(2006) The iminosugar isofagomine increases the activity of
N370S mutant acid beta-glucosidase in Gaucher ﬁbroblasts by
several mechanisms. Proc. Natl Acad. Sci. USA 103, 13813–
13818.
Stone D. L., Tayebi N., Orvisky E., Stubbleﬁeld B., Madike V. and
Sidransky E. (2000) Glucocerebrosidase gene mutations in patients
with type 2 Gaucher disease. Hum. Mutat. 15, 181–188.
Sun Q. Y., Guo J. F., Wang L., Yu R. H., Zuo X., Yao L. Y., Pan Q., Xia
K. and Tang B. S. (2010a) Glucocerebrosidase gene L444P
mutation is a risk factor for Parkinson’s disease in Chinese
population. Mov. Disord. 25, 1005–1011.
Sun Y., Liou B., Ran H. et al. (2010b) Neuronopathic Gaucher disease
in the mouse: viable combined selective saposin C deﬁciency and
mutant glucocerebrosidase (V394L) mice with
glucosylsphingosine and glucosylceramide accumulation and
progressive neurological deﬁcits. Hum. Mol. Genet. 19, 1088–
1097.
Suzuki Y., Ogawa S. and Sakakibara Y. (2009) Chaperone therapy for
neuronopathic lysosomal diseases: competitive inhibitors as
chemical chaperones for enhancement of mutant enzyme
activities. Perspect. Medicin. Chem. 3, 7–19.
Swan M. and Saunders-Pullman R. (2013) The association between ß-
glucocerebrosidase mutations and parkinsonism. Curr. Neurol.
Neurosci. Rep. 13, 368.
Tamboli I. Y., Hampel H., Tien N. T., Tolksdorf K., Breiden B.,
Mathews P. M., Saftig P., Sandhoff K. and Walter J. (2011)
Sphingolipid storage affects autophagic metabolism of the amyloid
precursor protein and promotes Abeta generation. J. Neurosci. 31,
1837–1849.
Tan E. K., Tong J., Fook-Chong S., Yih Y., Wong M. C., Pavanni R.
and Zhao Y. (2007) Glucocerebrosidase mutations and risk of
Parkinson disease in Chinese patients. Arch. Neurol. 64, 1056–
1058.
Tayebi N., Cushner S. and Sidransky E. (1996) Differentiation of
the glucocerebrosidase gene from pseudogene by long-template
PCR: implications for Gaucher disease. Am. J. Hum. Genet. 59,
740–741.
Tayebi N., Callahan M., Madike V., Stubbleﬁeld B. K., Orvisky E.,
Krasnewich D., Fillano J. J. and Sidransky E. (2001) Gaucher
disease and parkinsonism: a phenotypic and genotypic
characterization. Mol. Genet. Metab. 73, 313–321.
Tayebi N., Walker J., Stubbleﬁeld B., Orvisky E., Lamarca M. E., Wong
K., Rosenbaum H., Schiffmann R., Bembi B. and Sidransky E.
(2003) Gaucher disease with parkinsonian manifestations: does
glucocerebrosidase deﬁciency contribute to a vulnerability to
parkinsonism? Mol. Genet. Metab. 79, 104–109.
Toft M., Pielsticker L., Ross O. A., Aasly J. O. and Farrer M. J. (2006)
Glucocerebrosidase gene mutations and Parkinson disease in the
Norwegian population. Neurology 66, 415–417.
Turpin J. C., DuboisG., BriceA.,MassonM., NadaudM.C., Boutry J.M.,
Schram A. W., Tager J. M. and Baumann N. (1988) Parkinsonian
symptomatology in a patient with type I (adult) Gaucher’s disease.
Lipid Storage Disord. NATO ASI Ser. 150, 103–105.
Vaccaro A. M., Motta M., Tatti M., Scarpa S., Masuelli L., Bhat M.,
Vanier M. T., Tylki-Szymanska A. and Salvioli R. (2010) Saposin
C mutations in Gaucher disease patients resulting in lysosomal
lipid accumulation, saposin C deﬁciency, but normal prosaposin
processing and sorting. Hum. Mol. Genet. 19, 2987–2997.
Varkonyi J., Rosenbaum H., Baumann N., Mackenzie J. J., Simon Z.,
Aharon-Peretz J., Walker J. M., Tayebi N. and Sidransky E. (2003)
Gaucher disease associated with parkinsonism: four further case
reports. Am. J. Med. Genet. A 116A, 348–351.
Vila M., Bove J., Dehay B., Rodrıguez-Muela N. and Boya P. (2011)
Lysosomal membrane permeabilization in Parkinson disease.
Autophagy 7, 98–100.
Wang Y., Liu L., Xiong J. et al. (2012) Glucocerebrosidase L444P
mutation confers genetic risk for Parkinson’s disease in central
China. Behav. Brain Funct. 1, 8–57.
Westbroek W., Gustafson A. M. and Sidransky E. (2011) Exploring the
link between glucocerebrosidase mutations and parkinsonism.
Trends Mol. Med. 17, 485–493.
Winder-Rhodes S. E., Evans J. R., Ban M., Mason S. L., Williams-Gray
C. H., Foltynie T., Duran R., Mencacci N. E., Sawcer S. J. and
Barker R. A. (2013) Glucocerebrosidase mutations inﬂuence the
natural history of Parkinson’s disease in a community-based
incident cohort. Brain 136, 392–399.
Wu Y. R., Chen C. M., Chao C. Y., Ro L. S., Lyu R. K., Chang K. H.
and Lee-Chen G. J. (2007) Glucocerebrosidase gene mutation is a
risk factor for early onset of Parkinson disease among Taiwanese.
J. Neurol. Neurosurg. Psychiatry 78, 977–979.
Xilouri M., Vogiatzi T., Vekrellis K., Park D. and Stefanis L. (2009)
Abberant alpha-synuclein confers toxicity to neurons in part
through inhibition of chaperone-mediated autophagy. PLoS ONE
4, e5515.
Xu Y. H., Xu K., Sun Y. et al. (2014) Multiple pathogenic proteins
implicated in neuronopathic Gaucher disease mice. Hum. Mol.
Genet. 23, 3943–3957.
Yap T. L., Gruschus J. M., Velayati A., Westbroek W., Goldin E.,
Moaven N., Sidransky E. and Lee J. C. (2011) Alpha-synuclein
interacts with glucocerebrosidase providing a molecular link
between Parkinson and Gaucher diseases. J. Biol. Chem. 286,
28080–28088.
Yoshida H. (2007) ER stress and diseases. FEBS J. 274, 630–658.
Yu Z., Wang T., Xu J. et al. (2015) Mutations in the glucocerebrosidase
gene are responsible for Chinese patients with Parkinson’s disease.
J. Hum. Genet. 60, 85–90.
Zhang X., Bao Q. Q., Zhuang X. S. et al. (2012) Association of common
variants in the glucocerebrosidase gene with high susceptibility to
Parkinson’s disease among Chinese. Chin. J. Physiol. 55, 398–404.
Ziegler S. G., Eblan M. J., Gutti U., Hruska K. S., Stubbleﬁeld B. K.,
Goker-Alpan O., LaMarca M. E. and Sidransky E. (2007)
Glucocerebrosidase mutations in Chinese subjects from Taiwan
with sporadic Parkinson disease. Mol. Genet. Metab. 91, 195–200.
Zokaei N., McNeill A., Proukakis C. et al. (2014) Visual short-term
memory deﬁcits associated with GBA mutation and Parkinson’s
disease. Brain 137(Pt 8), 2303–2311.
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
International Society for Neurochemistry, J. Neurochem. (2016) 139 (Suppl. 1), 77--90
90 A. Migdalska-Richards and A. H. V. Schapira
